Pfizer Inc. (NYSE:PFE) secured a $10 billion deal to accumulate weight problems drug developer Metsera, Inc. (NASDAQ:MTSR), beating out Novo Nordisk A/S (NYSE:NVO) after a heated bidding battle that captivated Wall Road.
Metsera Board Backs Deal
Underneath the deal, Pfizer pays $86.25 per share, consisting of $65.60 in money and a contingent worth proper price as much as $20.65 per share, relying on future milestones.
Metsera’s board unanimously backed Pfizer’s provide on Friday, and really helpful shareholders approve the deal at their upcoming Nov. 13 assembly.
Pfizer appeared to have finalised the deal in September, earlier than Novo jumped in final week with an unsolicited provide, sparking a bidding battle for a coveted asset within the rising weight-loss market. Metsera’s shares jumped over 30% amid the chatter this week.
The corporate stated Novo’s proposal posed “unacceptably excessive authorized and regulatory dangers” after the Federal Commerce Fee (FTC) warned {that a} merger with Novo may elevate antitrust issues.
Additionally Learn: Pfizer Accuses Novo Nordisk Of Antitrust Violations In Metsera Takeover Battle
Novo Nordisk, which briefly appeared to have the higher hand, has been in search of to get better market floor misplaced to Eli Lilly (NYSE:LLY) within the weight-loss drug sector.
Pfizer Bets Massive On Subsequent-Gen Weight-Loss Medication
Metsera’s pipeline contains MET-097i and MET-233i, an experimental amylin analog. Analysts at Leerink Companions estimate the 2 medicine may attain $5 billion in mixed peak annual gross sales, based on a Reuters report.
The acquisition comes as Pfizer faces declining COVID-19 product gross sales, with third-quarter income down 6% 12 months over 12 months to $16.65 billion, whereas Ozempic-maker Novo Nordisk posted an 11% rise in constant-currency gross sales to $11.75 billion, pushed by weight problems and diabetes therapies.
Based on Benzinga’s Edge Inventory Rankings, Pfizer demonstrates a gentle upward trajectory in brief and medium-term intervals however a downward development within the long-term. Click on right here for an in depth breakdown of its efficiency, together with comparisons to its friends and rivals.
Learn Subsequent:
Disclaimer: This content material was partially produced with the assistance of AI instruments and was reviewed and printed by Benzinga editors.
Picture by way of Shutterstock
